Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhen people search for a weight loss injection beginning with R, they're usually thinking of Rybelsus — or they've heard the name somewhere and aren't sure what it is. Here's the short answer: Rybelsus is a tablet, not an injection, and it's licensed in the UK for type 2 diabetes, not weight management. The licensed injections for weight loss in the UK are Mounjaro (tirzepatide) and Wegovy (semaglutide), both prescription-only medicines that require a clinical assessment before a prescriber can authorise them.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Imagine you've been scrolling through a forum or overheard a conversation at the gym. Someone mentioned a weight loss jab beginning with R. You type it into a search bar and get a wall of results, some confident, some contradictory. It's a reasonable thing to feel confused about.
Rybelsus is the name most people land on. It does contain semaglutide (the same active ingredient found in Wegovy) and semaglutide is genuinely effective for weight loss in clinical trials. But Rybelsus is licensed by the MHRA for type 2 diabetes management, at doses of 3mg, 7mg and 14mg daily. Those are entirely different dose levels from the Wegovy weight-loss tablet schedule (which runs from 1.5mg up to 25mg and only received UK approval for weight management in June 2026). More importantly, Rybelsus is a tablet, not an injection. So if your search was for an injection specifically, Rybelsus isn't the answer on either count. The NHS's information on semaglutide sets this out clearly and is worth reading if you want to understand how the two products differ.
Sometimes people also search for Saxenda, a liraglutide injection that begins with S, or Ozempic, another semaglutide injection beginning with O that is licensed for diabetes, not weight loss. If you want a full picture of which injections are actually approved for weight management in the UK, that page covers the options without the noise.
The two injections licensed for weight management in the UK are Mounjaro and Wegovy. Both are once-weekly subcutaneous injections; both are prescription-only.
Mounjaro (tirzepatide) works on two gut-hormone receptors simultaneously (GIP and GLP-1) which makes it the only dual-agonist weight-loss medicine currently available in the UK. Treatment starts at 2.5mg. The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported average weight reductions of around 20–21% at the highest dose over 72 weeks. If you're curious about weight loss injections beginning with T, tirzepatide is the relevant name there.
Wegovy (semaglutide) is a single-pathway GLP-1 receptor agonist. The standard titration runs from 0.25mg up to a 2.4mg maintenance dose; the MHRA also approved a 7.2mg dose in January 2026, with a dedicated single-dose pen following in April 2026. STEP 1 trial data showed roughly 15% average weight loss over 68 weeks at 2.4mg. For more background on how weight loss injections work as a category, that page gives a broader overview.
There are practical differences beyond the trial numbers. Mounjaro uses a dual-receptor mechanism; Wegovy acts on one. The dose escalation schedules differ. Which suits a given person depends on their medical history, any existing conditions and what a prescriber determines is clinically appropriate, it genuinely isn't a decision to make from a forum post.
Both medicines are licensed for adults with a BMI of 30 or above, or 27 or above when a weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea is present. Lower thresholds can apply for some ethnic backgrounds under UK guidance. Neither medicine is licensed for people under 18, and both are not recommended during pregnancy, while breastfeeding or when actively trying to conceive.
Common side effects with both treatments follow a broadly gastrointestinal pattern: nausea, loose stools, constipation, reflux, and sometimes fatigue or headache, particularly after starting or when a dose goes up. These often ease as the body adjusts. If you develop severe, persistent stomach pain that radiates towards your back, get medical help promptly, the MHRA highlighted acute pancreatitis as a known, if infrequent, risk in a safety update in early 2026. You can report any suspected side effects through the MHRA's Yellow Card scheme.
For Mounjaro specifically, women taking oral contraceptives should add a non-oral method for the first four weeks of treatment and for four weeks after any dose increase, because pill absorption may be reduced. That's a detail worth raising at consultation, it's the kind of thing a prescriber catches that a self-directed internet search often misses. Worth knowing before you start, not after.
When it comes to buying safely, the process of getting a weight loss injection through a legitimate UK route always involves a proper clinical assessment. Pens offered online without that step are a serious safety risk, the MHRA has seized approximately 20 million doses of illegally traded weight-loss medicines, worth around £45 million, and found counterfeit tirzepatide in at least one UK manufacturing raid. Any pharmacy dispensing these medicines should be verifiable on the GPhC register.
NHS access to both injections exists but remains limited. Tirzepatide is being phased in through GP practices from 2025, with eligibility currently tied to high BMI and multiple weight-related conditions. Wegovy is available via specialist weight management services, though waiting lists vary widely. For a clear picture of weight management treatment options more broadly, that page sets out what's available and through which route.
Private treatment costs more than nothing, and it's worth understanding what a legitimate price should include. Any provider quoting a headline figure for these medicines should be bundling in the clinical consultation, the prescription, and ideally aftercare, separate fees for those are common and worth checking. You can see what a full private weight loss treatment through our prescribers covers and judge for yourself whether it makes sense for your situation. If you're curious about tanning injections and their unproven claims, that page explains why they're a different matter entirely from licensed weight-loss medicines.
Treatment starts with a free consultation, your answers go to a real prescriber, not an algorithm, on the same day. If you'd like to understand more about who reviews consultations at nume, our clinical team page is there. If you're based in the area and want to explore your options locally, you can find out more about weight loss injections in Stoke-on-Trent and whether treatment might be right for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.